BG-12: two analyses of safety results


REPORT FROM THE AMERICAN ACADEMY OF NEUROLOGY (AAN) ANNUAL MEETING, SAN DIEGO, CA, MARCH 16-23, 2013 – An integrated analysis of BG-12 trials indicates that there is a low incidence of serious adverse events during treatment although flushing and gastrointestinal effects are common (Phillips et al. AAN 2013; abstract S30.003).

It takes 30 seconds

Recommend to a Colleague

Related Posts

Go back to home page